Now the companies have announced results of a 102 week Phase III study for linagliptin (trade
name Trajenta® in Europe), which show meaningful and durable reductions
in blood glucose for adults with type 2 diabetes (T2D). In the two-year study presented today at the 47th Annual Meeting of the European Association for the Study of Diabetes
(EASD), the DPP-4 inhibitor linagliptin showed a favourable safety
profile and lowered HbA1c levels by 0.8% over the long term in those
patients treated with linagliptin for the full study period.
Researchers conclude that, these results show that the efficacy
achieved by linagliptin is reliable and meaningful in a clinical
setting, but also that it is durable over the long term. This is
especially important in chronic conditions such as type 2 diabetes.
The data from these patients demonstrate the efficacy and tolerability of linagliptin as mono-, dual- (plus metformin or initial combination with pioglitazone) or triple (plus metformin
and sulphonylurea) oral therapy over a period of 102 weeks. Reductions
in HbA1c of 0.8% after 24 weeks of blinded treatment were seen to be
durable over the additional 78 weeks. Overall, the rate of hypoglycaemic
events was low and body weight remained unchanged.
More..
